Total Equity
Regeneron Pharmaceuticals Total Equity increased by 0.5% to $31.42B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.9%, from $29.39B to $31.42B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 23.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A growing equity base suggests increasing value for shareholders, though aggressive share buybacks can intentionally reduce this figure.
Detailed definition
The residual interest in the assets of the company after deducting all liabilities. It represents the net book value of...
Peer comparison
Used to calculate Return on Equity (ROE), a primary measure of how effectively management is using shareholder capital to generate profit.
total_stockholders_equityHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.13B | $17.26B | $18.77B | $19.91B | $20.69B | $21.44B | $22.66B | $23.50B | $24.02B | $24.90B | $25.97B | $26.99B | $28.21B | $29.33B | $29.35B | $29.39B | $29.94B | $30.96B | $31.26B | $31.42B |
| QoQ Change | — | +14.1% | +8.8% | +6.1% | +3.9% | +3.6% | +5.7% | +3.7% | +2.2% | +3.7% | +4.3% | +3.9% | +4.5% | +4.0% | +0.1% | +0.1% | +1.9% | +3.4% | +1.0% | +0.5% |
| YoY Change | — | — | — | — | +36.8% | +24.2% | +20.8% | +18.0% | +16.1% | +16.2% | +14.6% | +14.9% | +17.4% | +17.8% | +13.0% | +8.9% | +6.1% | +5.6% | +6.5% | +6.9% |
Total Equity at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total equity?
- Regeneron Pharmaceuticals (REGN) reported total equity of $31.42B in Q1 2026.
- How has Regeneron Pharmaceuticals's total equity changed year-over-year?
- Regeneron Pharmaceuticals's total equity increased by 6.9% year-over-year, from $29.39B to $31.42B.
- What is the long-term trend for Regeneron Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total equity has grown at a 23.2% compound annual growth rate (CAGR), from $11.03B to $31.26B.
- What does total equity mean?
- The net worth of the company belonging to the owners, calculated as total assets minus total liabilities.